Bicycle Therapeutics
BCYC· Manufacturing· Fiscal year ends in December
Kevin Lee, Ph.D., MBA is the CEO of Bicycle Therapeutics and was paid $6.3M in FY2025 (Dec), up 31%.
Executives3
See all- 1Kevin Lee, Ph.D., MBAChief Executive OfficerFY2025
- 2Michael Skynner, Ph.D.Chief Scientific OfficerFY2025
- 3Alistair MilnesChief Corporate Development OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allBicycle Therapeutics paid its 3 named executives $11.0M in total in FY2025 (Dec). CEO Kevin Lee, Ph.D., MBA was paid $6.3M of that.
| Name | |||
|---|---|---|---|
| Kevin Lee, Ph.D., MBAChief Executive Officer | Not disclosed | ||
| Michael Skynner, Ph.D.Chief Scientific Officer | Not disclosed | Not disclosed | |
| Alistair MilnesChief Corporate Development Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers19
See allThe FY2024 (Dec) proxy of Bicycle Therapeutics names 19 peer companies for pay. Among Bicycle Therapeutics and these peers, CEO pay was the lowest of 9 and total shareholder return was 6th highest of 9.
9th highest of 9in Bicycle Therapeutics and its pay peers, FY2024 (Dec) by CEO pay:
6th highest of 9in Bicycle Therapeutics and its pay peers, FY2024 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board1
See all- Felix BakerChair · 1 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 22, 2026 | FY2025 |
| Annual report | 10-K | Mar 17, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 23, 2025 | FY2024 |
| Annual report | 10-K | Feb 25, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 15, 2024 | FY2023 |
| Annual report | 10-K | Feb 20, 2024 | FY2023 |